SAN JOSE, Calif.--(BUSINESS WIRE)--DFine Inc., the World’s leading developer of Radio Frequency Kyphoplasty products, minimally invasive solutions for treating vertebral compression fractures (VCFs), today announced the appointment of Mr. Kevin Mosher, as Chief Executive Officer, effective November 16, 2009.
Mr. Mosher comes to DFine from Nobel Biocare, where he served as President of their North American division. During his tenure at Nobel Biocare, Mosher helped grow and build an organization known for its stellar sales execution and consistent profitability. He was a member of the Executive Committee since joining in 2004, and helped guide the organization through several acquisitions and a more than doubling of the company’s organic revenues.
“DFine has a premier Kyphoplasty platform that is poised to become a leader in the minimally invasive treatment of VCFs,” said Mosher. “I look forward to building upon this impressive market entry, and driving this world class organization to the next level.”
Throughout his career, Mosher has distinguished himself as a builder of businesses that consistently exceed their executional goals. Prior to his position at Nobel Biocare, Mosher served as President of medical device manufacturer Masimo Corporation, and spent over 11 years rising through the sales and marketing ranks at medical device stalwarts such as Baxter Healthcare and Johnson & Johnson. Mosher holds an Applied Engineering degree from the U.S. Naval Academy.
“After conducting an extensive nationwide search, DFine’s Board of Directors believes we have chosen an excellent leader who will guide and focus our efforts in the coming years. Kevin Mosher brings the perfect combination of vision and execution to his new role,” said Russell Hirsch Ph.D. M.D., Managing Director of Prospect Venture Partners. Csaba Truckai, founder and current CEO of DFine says, “During this natural evolution of our team, we will benefit tremendously from Kevin’s leadership, experience and his proven ability to grow businesses. I look forward to working closely with him in my new role as Chief Technology Officer of DFine.”
Dr. Rodney Perkins, Chairman of the Board added, “The combination of Kevin’s strategic sales and marketing experience, Csaba’s innovative product development and our strong financial support positions us well to become the leader in the next generation of minimally invasive vertebral compression fracture treatments.”
ABOUT DFine, Inc.
DFine, Inc. (www.dfineinc.com), founded in 2004, is a medical device company based in San Jose, California.
DFine Europe GmbH located in Mannheim, Germany is a subsidiary of DFine, Inc., and a member of the German Medical Technology Association.
DFine’s mission is to develop and market medical devices that treat vertebral compression fractures and other spinal disorders in a minimally invasive manner to improve patient quality of life.
DFine’s RF Kyphoplasty procedure with the StabiliT™ Vertebral Augmentation System is the next generation in kyphoplasty. It combines the benefits of site-specific cavity creation, controlled cement delivery, and potential for height restoration with ultra-high viscosity StabiliT™ ER2 Bone Cement. During the procedure, radiofrequency energy is applied to specially formulated energy-responsive bone cement to create ultra-high viscosity cement. The cement is delivered into a cavity within the vertebra using a hand switch that allows the physician to remain up to 10 feet from the fluoroscopic field, potentially reducing the physician’s exposure to radiation.
The first RF Kyphoplasty cases were conducted in Europe as part of the SPACE clinical study in December of 2006. US spine specialists began performing RF Kyphoplasty with the StabiliT™ Vertebral Augmentation System in April of 2008, while commercialization in Europe began in February of 2009.
Contact:
DFine David Simpson, 408-396-9800 Vice President Sales & Marketing daves@dfineinc.com
